Status:
UNKNOWN
Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
This study is a prospective, open label, controlled, single center study. 40 patients will be recruited for the study, according to patients' inflow and meeting eligibility criteria. Primary Goal \*...
Detailed Description
Primary Endpoint Parameter • Primary study endpoint will be to establish the safety of using the GlucoSat technology as a non-invasive glucose level measurement technology. Safety will be established...
Eligibility Criteria
Inclusion
- Male/Female aged 18 and up.
- Subject was diagnosed as a diabetes patient or healthy subject.
- Subject able to comprehend and give informed consent for participation in this study.
- Signed Informed Consent Form
Exclusion
- Pregnancy or breast feeding.
- Patients treated with steroid.
- Concomitant Coumadin use
- Recent (within the last 3 months) myocardial infarction or CVA (stroke).
- Any chronic unstable disease within the last 3 months.
- Acute bleeding disorders.
- HIV positive.
- Hepatitis B/C positive.
- BMI\>37
- Needing emergency surgery
- Known cognitive or psychiatric disorder
- Physician objection
- Concurrent participation in any other clinical trial
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00451334
Last Update
March 23 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf-Harofeh Medical Center
Zrifin, Israel, 70300